Paula R Brantley

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background Recent studies have reported that the clinical benefit of interleukin-2 (IL-2) immunotherapy for metastatic renal cell carcinoma (mRCC) and melanoma (mM) may be underestimated by typically reported outcomes, instead suggesting that progression-free survival or “disease control rate” (DCR) may provide a more meaningful prognostic indicator [1].(More)
  • 1